Press & News
LA JOLLA—The decision between scrambled eggs or an apple for breakfast probably won’t make or break your day. However, for your cells, a decision between similar microscopic nutrients could determine …
LA JOLLA—Within each of our cells, long strands of DNA are folded into chromosomes and capped with protective structures called telomeres. But telomeres shorten as we age, eventually getting so …
LA JOLLA—Salk Institute Assistant Professor Jesse Dixon has been named a 2024 Pew Biomedical Scholar by The Pew Charitable Trusts. This honor provides funding to early-career investigators who demonstrate outstanding …
LA JOLLA—Immunotherapy has revolutionized the way we treat cancer in recent years. Instead of targeting the tumor itself, immunotherapies work by directing patients’ immune systems to attack their tumors more …
LA JOLLA—The Salk Institute will receive a four-year, $5 million gift from the Paul M. Angell Family Foundation to support pancreatic cancer research. The project’s leaders, Salk Assistant Professor Dannielle …
LA JOLLA—Salk Institute Professor Susan Kaech has been elected to the U.S. National Academy of Sciences. Kaech is one of 120 new members and 24 international members to be elected …
LA JOLLA—Pancreatic cancer has the highest mortality rate of all major cancers and is projected to become the second-leading cause of cancer-related deaths in the United States by 2030. It …
LA JOLLA—Lung adenocarcinoma is the most common lung cancer and the cause of most cancer-related deaths in the United States. There are several ways lung adenocarcinoma can arise, one of …
LA JOLLA—Salk Professor Ronald Evans has been named the 2024 recipient of the Japan Prize in the field of Medical Science and Pharmaceutical Science. The Japan Prize Foundation awards this …
LA JOLLA—The Salk Institute marks 50 years as a National Cancer Institute (NCI)-Designated Cancer Center with good news: NCI has renewed the designation and grant support for another five years.
With …
LA JOLLA—Pancreatic cancer is one of the deadliest cancers—only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly …
LA JOLLA—Regulatory T cells are specialized immune cells that suppress the immune response and prevent the body from attacking its own cells. Understanding how these cells work is key to …
LA JOLLA—Salk Institute Assistant Professor Christina Towers received a five-year, $2.85 million National Institutes of Health (NIH) Director’s New Innovator Award from the NIH Common Fund’s High-Risk, High-Reward Research program. …
LA JOLLA (September 25, 2023)—Salk Institute Assistant Professors Christina Towers and Deepshika Ramanan were named V Scholars by the V Foundation for Cancer Research. They will each receive $600,000 over …
LA JOLLA—Immunotherapy, which uses the body’s own immune system to fight cancer, is an effective treatment option, yet many patients do not respond to it. Thus, cancer researchers are seeking …
SEMINAR: Cancer Center Trainee Research Seminar
WHEN: Wednesday, November 20, 2024 at NOON
SPEAKER: Alex Moyzis, PhD – Shadel Lab
TALK TITLE: Utilizing Oxidative Mitohormesis to Combat CD8+ T Cell Exhaustion
SPEAKER: Nasiha Ahmed, PhD – Hargreaves Lab
TALK TITLE: Investigating the dynamics ofBAF complex phosphorylationinRTK signaling
HOSTS: Salk Cancer Center
LOCATION: Trustees’ Room
2023 Padres Pedal the Cause
Padres Pedal the Cause is Curebound’s largest signature event, bringing together thousands of participants each year to raise money for collaborative cancer research. Hosted in partnership with the Padres, “Pedal” is San Diego’s most impactful fundraising experience with over $18 million raised to date to fund 80+ innovative research grants in all types of cancer. This year’s event raised $3,253,032 .
Cancer Research Pilot Grant Portfolio »
